These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25871477)

  • 61. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
    Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
    J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
    Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
    Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
    Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis.
    Miyamoto E; Chen-Yoshikawa TF; Ueshima C; Yoshizawa A; Hamaji M; Yamamoto T; Kawada K; Haga H; Sakai Y; Date H
    J Surg Oncol; 2018 Jun; 117(7):1405-1412. PubMed ID: 29663398
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
    Aoki T; Hino M; Koh K; Kyushiki M; Kishimoto H; Arakawa Y; Hanada R; Kawashima H; Kurihara J; Shimojo N; Motohashi S
    Pediatr Blood Cancer; 2016 Aug; 63(8):1461-4. PubMed ID: 27135656
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Frequent PD-L1 expression in testicular germ cell tumors.
    Fankhauser CD; Curioni-Fontecedro A; Allmann V; Beyer J; Tischler V; Sulser T; Moch H; Bode PK
    Br J Cancer; 2015 Jul; 113(3):411-3. PubMed ID: 26171934
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer.
    Wang L; Ren F; Wang Q; Baldridge LA; Monn MF; Fisher KW; Sheng W; Zhou X; Du X; Cheng L
    Mol Diagn Ther; 2016 Apr; 20(2):175-81. PubMed ID: 26891728
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
    Rodić N; Anders RA; Eshleman JR; Lin MT; Xu H; Kim JH; Beierl K; Chen S; Luber BS; Wang H; Topalian SL; Pardoll DM; Taube JM
    Cancer Immunol Res; 2015 Feb; 3(2):110-5. PubMed ID: 25370533
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A High RORγT/CD3 Ratio is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells).
    Yoshida N; Kinugasa T; Miyoshi H; Sato K; Yuge K; Ohchi T; Fujino S; Shiraiwa S; Katagiri M; Akagi Y; Ohshima K
    Ann Surg Oncol; 2016 Mar; 23(3):919-27. PubMed ID: 26564244
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
    Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T
    J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
    Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
    Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
    Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
    Madore J; Vilain RE; Menzies AM; Kakavand H; Wilmott JS; Hyman J; Yearley JH; Kefford RF; Thompson JF; Long GV; Hersey P; Scolyer RA
    Pigment Cell Melanoma Res; 2015 May; 28(3):245-53. PubMed ID: 25477049
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
    Chang J; Zhu GA; Cheung C; Li S; Kim J; Chang AL
    JAMA Dermatol; 2017 Apr; 153(4):285-290. PubMed ID: 28259105
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
    Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
    Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
    Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
    [No Abstract]   [Full Text] [Related]  

  • 79. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.
    Paiva B; Azpilikueta A; Puig N; Ocio EM; Sharma R; Oyajobi BO; Labiano S; San-Segundo L; Rodriguez A; Aires-Mejia I; Rodriguez I; Escalante F; de Coca AG; Barez A; San Miguel JF; Melero I
    Leukemia; 2015 Oct; 29(10):2110-3. PubMed ID: 25778100
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.